Fireside Chat, Interview
Regeneron CEO Dr. Leonard Schleifer on Science-Driven Success
- Regeneron's founding philosophy rejects top-down target selection; the company operates on the principle that success is achieved only by "going where the science is right" rather than identifying desired therapeutic areas first.
- The company was founded in 1988 by Dr. Leonard Schleifer and Dr. George Yancopoulos, both MD-PhDs, after Schleifer's mentor discouraged him from pursuing a drug company in neuroscience.
- Initial early-stage strategy focused on neurotrophic factors for neurodegenerative diseases, a concept that Schleifer admitted was "naive" and initially viewed as a path to quick cures for Lou Gehrig's and Alzheimer's diseases.
- The company raised $99 million in its 1991 IPO, yet endured 23 years of annual losses before achieving profitability and becoming a major healthcare business in 2011.
- Current operations employ approximately 15,000 people in 2025, with 12 approved or authorized drugs globally.
- Dupixent stands as the company's largest product, approved for a wide range of Type 2 allergic diseases including atopic dermatitis, asthma, COPD, nasal polyps, eosinophilic esophagitis, bullous pemphigus, and chronic spontaneous urticaria (CSU).
- The pipeline contains nearly 50 drug candidates targeting therapeutic areas such as obesity, multiple myeloma, lung cancer, and the company's original focus on allergic diseases.
- Regeneron has contributed to the sequencing of approximately 3 million people, representing half of the global fully sequenced population, with data linked to anonymized medical records.
- The company is actively pursuing the sequencing of 50 million people to leverage genetic data for identifying disease patterns and improving diagnostic precision.
- Regarding neurodegenerative diseases, Dr. Schleifer expresses optimism that therapies will soon be able to arrest conditions like Alzheimer's, Parkinson's, and ALS, particularly if administered before symptom onset.
- Technological adoption includes utilizing AI to improve protocol drafting and regulatory document archetypes, though Schleifer notes that AI is not yet capable of single-handedly discovering or designing complex new drugs.
- The company views AI's primary industry utility as identifying patterns within vast genetic and medical record datasets, aiming to reduce the need for certain physical medical tests like colonoscopies in favor of targeted genetic screening.
- Regeneron invested in Truveta, a data organization founded by former Microsoft employees, with the goal of aggregating medical records for 90 million people to create a "Bloomberg Terminal of Health."
- Corporate governance excludes the practice of providing quarterly earnings guidance; Schleifer is the only S&P 500 CEO who refuses to disclose specific quarterly earnings figures.
- The company operates under a "do well by doing good" ethos, prioritizing patient benefit and physician ethics over short-term financial metrics.
- Dr. Schleifer cites the personal experience of raising a son with a genetic disability as a core motivator for the company's mission and ethical approach to medicine.